O-(1-isobutanoyloxyethyl) S-methyl thiocarbonate | 860035-07-0

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代缩醛
• 英文名称: O-(1-isobutanoyloxyethyl) S-methyl thiocarbonate
• 英文别名: 1-methylsulfanylcarbonyloxyethyl 2-methylpropanoate
• CAS: 860035-07-0
• 化学式: C₈H₁₄O₄S
• 分子量: 206.263
• InChiKey: HRMLDMALWZLZAF-UHFFFAOYSA-N

物化性质

• 沸点：
  -138.15℃[at 101 325 Pa]
• LogP：
  2.3 at 20℃

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  77.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  O-(1-isobutanoyloxyethyl) S-methyl thiocarbonate 在 lipase from Candida antarctica, immobilized on acrylic resin 作用下， 反应 16.0h， 以100%的产率得到1-((((methylthio)carbonyl)oxy)ethyl)isobutyrate
  参考文献：
  名称：

  MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE

  摘要：

  本发明提供了(3S)-氨甲基-5-己酸前药的介相形式及其制备方法和使用方法。

  公开号：

  US20090192222A1
• 作为产物：
  描述：

  (1-chloroethoxy)(methylsulfanyl)methanone 在 N,N-二异丙基乙胺 作用下， 以 异丁酸 为溶剂， 以97%的产率得到O-(1-isobutanoyloxyethyl) S-methyl thiocarbonate
  参考文献：
  名称：

  ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG

  摘要：

  本发明揭示了含有高负载加巴喷丁前药的持续释放口服剂型。

  公开号：

  US20100226981A1

文献信息

• [EN] COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：RESILIO THERAPEUTICS LLC

  公开号：WO2018085263A1

  公开（公告）日：2018-05-11

  Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that can metabolize under physiological conditions to ornithine. The pH and plasma stability of compounds of formula (II) is also described. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II).

  公开了化学式（II）的新化合物。化学式（II）的化合物包括鸟氨酸衍生物或在生理条件下可以代谢成鸟氨酸的化合物。还描述了化学式（II）的化合物的pH值和血浆稳定性。还公开了使用化学式（II）的化合物治疗神经退行性疾病如阿尔茨海默病的方法。
• [EN] PROTEASOME INHIBITING ß-LACTAM PRODRUGS USEFUL FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS<br/>[FR] PROMÉDICAMENTS À BASE DE SS-LACTAME INHIBITEURS DU PROTÉASOME UTILES POUR LE TRAITEMENT DU CANCER ET DE TROUBLES NEURODÉGÉNÉRATIFS
  申请人：VITA API

  公开号：WO2018115497A1

  公开（公告）日：2018-06-28

  The present invention relates generally to proteasome inhibiting β-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formulations of said compounds, and medical uses of said compounds and/or pharmaceutical compositions to treat cancer and neurodegenerative disorders.

  本发明通常涉及抑制蛋白酶体的β-内酰胺化合物，用于治疗癌症和神经退行性疾病。该发明还提供了所述化合物的药物组合物和延长释放配方，以及利用所述化合物和/或药物组合物治疗癌症和神经退行性疾病的医疗用途。
• Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
  申请人：Gallop A. Mark

  公开号：US20060111325A1

  公开（公告）日：2006-05-25

  Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

  3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药，包括3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的酰氧烷基氨基甲酸酯前药的药物组合物，制备3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，使用3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的前药的方法，以及用于治疗或预防痉挛或胃食管反流病等疾病或紊乱的药物组合物。还公开了适用于口服的酰氧烷基氨基甲酸酯前药、3-氨基丙基膦酸、3-氨基丙基膦酸和其类似物的持续释放口服剂型。
• Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
  申请人：Gallop A. Mark

  公开号：US20060111439A1

  公开（公告）日：2006-05-25

  Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof, pharmaceutical compositions of 3-aminopropylsulfinic acid and analogs thereof, methods of making prodrugs of 3-aminopropylsulfinic acid and analogs thereof, methods of using prodrugs of 3-aminopropylsulfinic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

  3-氨基丙磺酸及其类似物的酰氧烷基氨基甲酸酯前药，3-氨基丙磺酸及其类似物的药物组合物，制备3-氨基丙磺酸及其类似物的前药的方法，使用3-氨基丙磺酸及其类似物的前药的方法，以及用于治疗或预防痉挛性或胃食管反流病等疾病或紊乱的药物组合物已被披露。此外，还披露了适用于口服的3-氨基丙磺酸及其类似物的酰氧烷基氨基甲酸酯前药和持续释放口服剂型。
• Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
  申请人：Gallop Mark A.

  公开号：US20090216037A1

  公开（公告）日：2009-08-27

  Methods for synthesis of 1 -(acyloxy)-alkyl carbamates, particularly, the synthesis of 1 -(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1 -(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

  本文描述了合成1-(酰氧基)-烷基氨基甲酸酯的方法，特别是合成含有一级或二级胺药物的1-(酰氧基)-烷基氨基甲酸酯前药的方法。同时还描述了合成1-(酰氧基)-烷基N-羟基琥珀酰亚胺基碳酸酯的方法，这些中间体在合成1-(酰氧基)-烷基氨基甲酸酯中非常有用。